Master of Science in Counseling Research

Permanent URI for this collection

https://mcstor.library.milligan.edu/handle/11558/1128

Browse

Browsing Master of Science in Counseling Research by Subject "Buprenorphine"

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Buprenorphine MAT's Impact on Opioid Relapse
    (2022) Thomas, Alexandria; Drinnon, Joy
    In 2020, opioids were involved in 68,630 overdose deaths, which accounted for 74.8% of all drug overdose deaths (Centers for Disease Control and Prevention, 2022). In the past few decades, an increased understanding surrounding the neurological, and subsequent physiological, dependence caused by substances has shifted society’s ideology away from viewing addiction as a choice and instead towards a disease that has claimed the lives of millions. Opioid addiction as outlined by the 5th edition of the Diagnostic and Statistical Manual, indirectly effects arguably all Americans due to the financial toll and how this disease impacts not only loved ones, but also communities surrounding individuals suffering from addiction. Buprenorphine, a Food and Drug Administration (FDA) approved pharmacological treatment option for opioid use disorder, has yielded drastically positive outcomes, especially when combined with behavioral health interventions. More specifically, Greiner et al. (2021) found that of those who retained treatment, fewer met relapse criteria (16.4% vs 38.9%), they had fewer opioid use days in the past month (4.4 days vs 9.8 days), and they had less stimulant use (15.2% vs 27.7%). An opposition to MAT options such as Buprenorphine, neglects the empirically sound evidence, disregards the importance of combating the opioid epidemic, and exhibits a lack of urgency to save lives. It is important to note that buprenorphine at any dose has been found to retain patients in recovery better than a placebo (Reimer et al., 2020). The availability of these treatment options is vital to preserving the health of Americans and combating years of stigma attributing to barriers individuals face when receiving addictions treatment.